Pathway analysis revealed significant downregulation of noncanonical NF-κB signaling in IBD patients responsive to anti-TNFα therapy compared to untreated IBD patients and IBD patients treated with other (non-anti-TNF) medications (Figures 2C–F). The gene discussed is TNF; the disease is inflammatory bowel disease.